JAMP-EZETIMIBE 10 MG — DIN 02423235
EZETIMIBE : 10 MG · JAMP PHARMA CORPORATION · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is JAMP-EZETIMIBE?
JAMP-EZETIMIBE 10 MG contains EZETIMIBE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02423235, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Sep-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-EZETIMIBE used for?
JAMP-Ezetimibe (Ezetimibe Tablets) is indicated as an adjunct to lifestyle changes, including diet, when the response to diet and other non-pharmacological measures alone has been inadequate. JAMP-Ezetimibe, administered alone or with an HMG-CoA reductase inhibitor (statin), is indicated for the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL C), apolipoprotein B (Apo B), and triglycerides (TG) and to increase high density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. JAMP-Ezetimibe, administered in combination with fenofibrate, is indicated for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia. JAMP-Ezetimibe, administered with a statin, is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH as an adjunct to treatments such as LDL apheresis or if such treatments are not possible. JAMP-Ezetimibe is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ezetimibe cost around the world?
Ezetimibe is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 35 | 100 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 17 | 79 | CZK███.██ |
| Belgium | public | 69 | 69 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 58 | 58 | EUR███.██ |
| South Africa | single exit price | 37 | 37 | ZAR███.██ |
| Italy | prezzo al pubblico (classe A) | 11 | 35 | EUR███.██ |
| United States | acquisition | 1 | 33 | USD███.██ |
| Greece | producer price (ex-factory) | 30 | 30 | EUR███.██ |
| United Arab Emirates | public | 29 | 29 | AED███.██ |
| Saudi Arabia | public | 15 | 21 | SAR███.██ |
| Luxembourg | reimbursement | 20 | 20 | EUR███.██ |
| Bahrain | retail (max) | 10 | 14 | BHD███.██ |
| Hungary | producer price (ex-factory) | 6 | 7 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
535 pack listings across 340 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Ezetimibe pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Ezetimibe in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
22 holders have a Canadian DIN containing Ezetimibe, across 26 DINs, of which 18 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NORA PHARMA INC | 3 | 1 | NRA-EZETIMIBE, NRA-EZETIMIBE TABLETS, PRIVA-EZETIMIBE | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 1 | EZETIMIBE, RIVA-EZETIMIBE | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 2 | 1 | IPG-EZETIMIBE, MAR-EZETIMIBE | Sourceable in Canada |
| ANGITA PHARMA INC. | 1 | 1 | AG-EZETIMIBE | Sourceable in Canada |
| APOTEX INC | 1 | 1 | APO-EZETIMIBE | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-EZETIMIBE | Sourceable in Canada |
| BIOMED PHARMA | 1 | 1 | BIO-EZETIMIBE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP-EZETIMIBE | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-EZETIMIBE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | SANDOZ EZETIMIBE | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | EZETIMIBE | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-EZETIMIBE | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | bottles of 100 and 500 tablets, and blister packs of 30 tablets (3x10 tablets) |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Ezetimibe |
|---|---|
| ATC code | C10AX09 |
| AHFS class | 24:06.05 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02423235 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2423235 |
| Brand name | JAMP-EZETIMIBE |
| Generic / active ingredient | EZETIMIBE : 10 MG |
| Market authorization holder | JAMP PHARMA CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | C10AX09 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AX |
| Current status | MARKETED |
| Status date | 15-Sep-2014 |
| Original market date | 2014-09-15 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Ezetimibe in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
18 of 26 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-EZETIMIBE | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02425610 |
| AG-EZETIMIBE | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02475898 |
| APO-EZETIMIBE | 10 MG | TABLET | APOTEX INC | MARKETED | 02427826 |
| AURO-EZETIMIBE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | 02469286 |
| BIO-EZETIMIBE | 10 MG | TABLET | BIOMED PHARMA | MARKETED | 02425211 |
| EZETIMIBE | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | 02431300 |
| EZETIMIBE | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02422549 |
| EZETIMIBE | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02478544 |
| EZETROL | 10 MG | Tablet | ORGANON CANADA INC. | MARKETED | 02247521 |
| M-EZETIMIBE | 10 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02467437 |
2 · Same class — other molecules in ATC C10AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ezetimibe | ACH-EZETIMIBE · ACT EZETIMIBE · AG-EZETIMIBE · APO-EZETIMIBE · +19 more | 26 | 18 | Yes |
| Alirocumab | PRALUENT | 5 | 3 | Yes |
| Lomitapide | JUXTAPID | 3 | 3 | Yes |
| Omega-3-Triglycerides Incl. Other Esters And Acids | FLEX 500 · HERBALIFELINE · OMEGA-3 · VASCEPA | 4 | 1 | Yes |
| Evolocumab | REPATHA | 2 | 1 | Yes |
| Inclisiran | LEQVIO | 1 | 1 | Yes |
| Evinacumab | EVKEEZA | 1 | 1 | Yes |
| Dextrothyroxine | CHOLOXIN - TAB 4MG · CHOLOXIN TAB 2MG · CHOLOXIN TABLET 4MG | 4 | 0 | Not in Canada |
| Omega-3-Triglycerides, Combinations | OMEGA-3 FACTORS WITH VITAMIN E | 1 | 0 | Not in Canada |
| Probucol | LORELCO | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AA | Atorvastatin · Cerivastatin · Fluvastatin · Lovastatin · Pravastatin · +2 more | 759 | 286 |
| C10AB | Bezafibrate · Clofibrate · Fenofibrate · Gemfibrozil | 87 | 13 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
| C10AD | Nicotinic Acid | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is JAMP-EZETIMIBE called?
The same molecule, Ezetimibe, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Atozet | Latin | Australia, Bahrain |
| EZETIMIB VIATRIS | Latin | Czechia |
| ATORIS PLUS | Latin | Czechia |
| Ezetast | Latin | Australia |
| EZETIMIBE/SIMVASTATIN SANDOZ | Latin | Australia |
| EZETORIN | Latin | Australia |
| Ezetrol | Latin | Australia, Bahrain, Czechia, Morocco, South Africa |
| Vytorin | Latin | Australia |
| INEGY | Latin | Bahrain, Czechia |
| ZETOVAR | Latin | Czechia |
| EZEN | Latin | Czechia |
| EZETIMIB MYLAN | Latin | Czechia |
| EZETIMIB/ATORVASTATIN STADA | Latin | Czechia |
| EZETIMIBE/SIMVASTATIN TEVA CR | Latin | Czechia |
| EZETIMIB TEVA | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.